Champions Oncology (Champions Oncology) Retained Earnings

: $-84.48 Mil (As of Jan. 2024)

View and export this data going back to 2007. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Champions Oncology's retained earnings for the quarter that ended in Jan. 2024 was $-84.48 Mil.

Champions Oncology's quarterly retained earnings declined from Jul. 2023 ($-79.88 Mil) to Oct. 2023 ($-81.95 Mil) and declined from Oct. 2023 ($-81.95 Mil) to Jan. 2024 ($-84.48 Mil).

Champions Oncology's annual retained earnings increased from Apr. 2021 ($-72.53 Mil) to Apr. 2022 ($-71.98 Mil) but then declined from Apr. 2022 ($-71.98 Mil) to Apr. 2023 ($-77.32 Mil).

Champions Oncology Retained Earnings Historical Data

The historical data trend for Champions Oncology's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Retained Earnings

Get a 7-Day Free Trial

-70.70

-72.89

-72.53

-71.98

-77.32

Champions Oncology Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Retained Earnings	Get a 7-Day Free Trial															-74.76	-77.32	-79.88	-81.95	-84.48

Champions Oncology Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Champions Oncology (NAS:CSBR) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Champions Oncology (Champions Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

2I3:Germany

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

Executives

Daniel Newman Mendelson	director	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris	director, officer: President	855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld	director	ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp.	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman	director, officer: Chief Executive Officer	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins	10 percent owner
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093